Opdivo 240 mg SDPF Injection (Nivolumab 240 mg SDPF Injection)

$8,495.00

– Prescription Required
– Free Next Day Delivery to Anywhere in CA and NY
– Free Same Day Delivery within 50-Mile Radius of ApoThera
– Concierge Pharmacy; Do NOT Accept Insurance
– Annual Concierge Pharmacy Membership Fee: $300/year
– Accept Credit Cards, Apple Pay and Zelle
– Do NOT accept manufacturer coupons
 
Physicians may send E-Prescriptions (E-Scripts) to:
ApoThera
45 Post, 2nd Floor
Irvine, CA 92618
Phone: (949)387-7711
Fax:      (949)387-7712
Colorectal Cancer
Metastatic
– Microsatellite instability-high or mismatch repair deficient
– 240 mg (flat dose) IV once every 2 weeks until disease progression or unacceptable toxicity
OR
– 3 mg/kg IV once every 2 weeks until disease progression or unacceptable toxicity
 
Head and Neck Cancer (Squamous Cell)
Recurrent or Metastatic
– 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity
 
Hepatocellular Carcinoma
– 240 mg (flat dose) IV once every 2 weeks until disease progression or unacceptable toxicity
OR
– 3 mg/kg IV once every 2 weeks (as a single agent) until disease progression or unacceptable toxicity
 
Hodgkin Lymphoma
– 3 mg/kg IV once every 2 weeks until disease progression or unacceptable toxicity
 
Melanoma
Adjuvant Treatment
– 240 mg (flat dose) IV once every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year
OR
– 3 mg/kg IV once every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year
 
Non-Small Cell Lung Cancer
Metastatic, Progressive (Monotherapy)
– 240 mg (flat dose) IV once every 2 weeks until disease progression or unacceptable toxicity
OR
– 3 mg/kg IV once every 2 weeks until disease progression or unacceptable toxicity
 
Renal Cell Cancer
– 240 mg (flat dose) IV once every 2 weeks until disease progression or unacceptable toxicity
 
Urothelial Carcinoma
Locally Advanced or Metastatic
– 240 mg (flat dose) IV once every 2 weeks until disease progression or unacceptable toxicity
OR
– 3 mg/kg IV once every 2 weeks until disease progression or unacceptable toxicity
 
Small Cell Lung Cancer
Progressive
– 3 mg/kg IV once every 2 weeks until disease progression or unacceptable toxicity
Combination Therapy
– 1 mg/kg IV once every 3 weeks (in combination with ipilimumab) for 4 doses, then, 3 mg/kg IV once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity
Manufacturer: Bristol Myers Squibb
NDC: 00003-3734-13-1 Categories: ,

1 Vial = 1 Unit

Description

IV Administration
– Administer as an IV infusion over 60 minutes through a line with a sterile, nonpyrogenic, low protein binding 0.2 to 1.2 micrometer in-line filter
– Do not administer other medications through the same IV line
– Flush IV line at the end of the infusion
 
Combination Therapy with Ipilimumab
– When administered in combination with ipilimumab, infuse nivolumab first followed by ipilimumab on the same day
– Use separate infusion bags and filters for each infusion
– If nivolumab therapy is withheld, ipilimumab should also be withheld
 
Storage
Intact Vials
– Store intact vials at 2°C to 8°C (36°F to 46°F)
– Do not freeze
– Protect from light
– Do not shake
 
IV Infusion Solution
– After preparation in NS or D5W, store the infusion solution at room temperature for no more than 8 hours (including infusion time) or refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours (including infusion time)
– Infusion must be completed within 24 hours of preparation
– Do not freeze solutions prepared for infusion.
 
Monitoring
– Hepatic and renal function tests (baseline and periodic)
– Thyroid function (baseline and periodically [at treatment day 1 and every 6 weeks])
– Blood glucose
– Monitor for signs/symptoms of adrenal insufficiency, hypophysitis, thyroid disorders, immune-mediated colitis, pneumonitis, rash/dermatologic toxicity, encephalitis (changes in neurologic function)
– Monitor for infusion reactions.
Tags: , , , , , , , , , , , , , , , , , , , , , , ,

Related Products